(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Turkey key underlying issue as Israel, Greece, Cyprus hold summit - 2Building a Maintainable Closet: Individual Excursions in Moral Style
- 3In these U.S. groups, deaths now exceed births. What’s happening?
- 4Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- 5Meet the Stars of the Feline World: Well known Pet Feline Varieties
- 3D Printers for Specialists
- Sexual violence is being used as a weapon in Sudan's war, doctors group says
- Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland
- How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- Ukraine demands army of 800,000 under peace plan
- Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- Extreme Manual for Picking a Camper Van
- From Novice to Master: Dominating a Side interest
